First-time generic approvals
Paroxetine oral suspension 10 mg/5 mL equiv base (equiv to Paxil oral suspension 10 mg/5 mL equiv base)
Paroxetine oral suspension 10 mg/5 mL equiv base (equiv to Paxil oral suspension 10 mg/5 mL equiv base)
APOTEX
Oxandrolone tablets, 2.5 mg (equiv to Oxandrin tablets, 2.5 mg)
Oxandrolone tablets, 10 mg (equiv to Oxandrin tablets, 10 mg)
SANDOZ
Ondansetron injection single (4 mg/2 mL) and multidose (40 mg/20 mL) vials (equiv to Zofran injection)
TEVA
Ondansetron injection premixed 32 mg/50 mL in 5% dextrose (equiv to Zofran injection premixed)
SICOR
Sulfacetamide topical suspension USP 10% (equiv to Klaron lotion)
FOUGERA
Trandolapril tablets, 1, 2, and 4 mg (equiv to Mavik tablets, 1, 2, and 4 mg)
TEVA
Medicare’s Drug Price Negotiations Could Impact Physician Reimbursement
September 19th 2024When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those whose services are covered by commercial insurance, could see lowered reimbursement.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
